Nanobiotix S.A. (NBTX) Form 6-K — Sep 24, 2026
Nanobiotix reported a H1 2026 net loss of €34.3 million versus €5.4 million a year earlier, with the wider loss driven mainly by €14.5 million of interest costs, including €9.6 million of fixed-rate interest on the HealthCare Royalty Partners royalty financing. Revenue and other income fell to €5.6 million from €26.6 million, but the decline reflects a one-off €21.2 million Janssen contract-modification gain in H1 2025 rather than deteriorating operations; operating expenses actually improved to €23.5 million from €25.8 million.
Key figures
- Revenue
- €3.6 million (H1 2026) vs €24.9 million (H1 2025); total revenue and other income €5.6 million vs €26.6 million
- Guidance
- Cash of €110.9 million expected to fund operations beyond the next twelve months
- Net Income
- €34.3 million net loss vs €5.4 million net loss in H1 2025
- Total Assets
- €128.3 million (€4,850K non-current + €123,481K current)
- Cash Position
- €110.9 million as of June 30, 2026
- Gross Proceeds
- €86.1 million (~$100 million) gross; €80.1 million net, May 2026 Global Offering
- Shares Offered
- 2,218,467 ordinary shares plus 345,099 pre-funded warrants
- Shares Outstanding
- 50825682
- Interest costs
- €14.5 million H1 2026 (incl. €9.6 million fixed-rate royalty financing interest) vs €4.2 million H1 2025
- Operating expenses
- €23.5 million H1 2026 vs €25.8 million H1 2025
- Operating cash burn
- €18.2 million used in operations H1 2026
- Orr converge phase2
- 85.7% (6/7), CR 57.1% (4/7)
AI analysis
Red flags4 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.